Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

We recently published a list of Jim Cramer Nailed These 11 Stock Picks. In this article, we are going to take a look at where ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...